Skip to main content
Figure 4 | Molecular Cancer

Figure 4

From: Antitumor activity of motesanib alone and in combination with cisplatin or docetaxel in multiple human non–small-cell lung cancer xenograft models

Figure 4

Effect of motesanib in combination with docetaxel on various NSCLC xenograft tumor models. Tumor volume (top) and body weight (bottom) over time in response to motesanib plus docetaxel. (A) A549 tumors treated with vehicle motesanib 7.5 mg/kg BID, docetaxel 5 mg/kg QW, or motesanib plus docetaxel at the same dose and schedule for 14 days. *P ≤ 0.02 for combination vs either single agent alone. (B) Calu-6 tumors treated with vehicle, motesanib 75 mg/kg BID, docetaxel 30 mg/kg QW, or motesanib plus docetaxel at the same dose and schedule for 17 days. ‡P < 0.005 for combination vs either single agent alone. †P < 0.0001 vs vehicle; §P < 0.0001 for combination vs vehicle or either single agent. Data are expressed as mean ± SE.

Back to article page

Molecular Cancer

ISSN: 1476-4598